$ZTS earnings report

Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance. AlphAI read Zoetis's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readZTS · Third Quarter 2026 · ended September 30, 2026

Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance

→Mixed quarter

Third-quarter revenue declined 1%, with a 6% U.S. decline and an 8% decline in companion animal revenue, while International revenue grew 4% and livestock revenue grew 7%. GAAP net income and diluted EPS declined, although adjusted diluted EPS increased 3% and full-year adjusted EPS guidance was raised.

Revenue
$2.39B
(1) % y/y
Q3 2026 U.S.
$1.25B
(6) % y/y
Gross margin · other
82.2 %
EPS · non-GAAP
$ 1.75
3% reported and 1% organic operational y/y
Full Year 2026 as of November 5, 2026 outlook
$9,220 to $9,320

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 Revenue (millions of dollars)GAAP$2.39B–(1) %
Q3 2026 Gross profit (millions of dollars)GAAP$1.69B––
Q3 2026 Cost of sales (millions of dollars)GAAP$698M–—
Q3 2026 Selling, general and administrative expenses (millions of dollars)GAAP$582M–—
Q3 2026 Research and development expenses (millions of dollars)GAAP$174M–(1)
Q3 2026 Amortization of intangible assets (millions of dollars)GAAP$31M–(3)
Q3 2026 Restructuring charges and certain acquisition and divestiture-related costs (millions of dollars)GAAP$43M–*
Q3 2026 Interest expense, net of capitalized interest (millions of dollars)GAAP$62M–7
Q3 2026 Other (income)/deductions-net (millions of dollars)GAAP$72M–*
Q3 2026 Income before provision for taxes on income (millions of dollars)GAAP$729M–(18)
Q3 2026 Provision for taxes on income (millions of dollars)GAAP$138M–(16)
Q3 2026 Net income attributable to Zoetis Inc. (millions of dollars)GAAP$591M–(18)
Q3 2026 Earnings per share attributable to Zoetis-dilutedGAAP$ 1.44–(12)
Q3 2026 Adjusted net income (millions of dollars)non-GAAP$720M–(5) %
Q3 2026 Adjusted diluted EPSnon-GAAP$ 1.75–3% reported and 1% organic operational
Q3 2026 Adjusted gross profit (millions of dollars)non-GAAP$1.70B––
Q3 2026 Adjusted cost of sales (millions of dollars)non-GAAP$694M–— %
Q3 2026 Adjusted cost of sales as a percent of revenuenon-GAAP29.0 %––
Q3 2026 U.S. gross marginother82.2 %––
Q3 2026 International gross marginother68.9 %––
Nine Months 2026 Revenue (millions of dollars)GAAP$7.12B–—
Nine Months 2026 Net income attributable to Zoetis Inc. (millions of dollars)GAAP$1.88B–(8)
Nine Months 2026 Earnings per share attributable to Zoetis-dilutedGAAP$ 4.51–(2)
Nine Months 2026 Adjusted net income (millions of dollars)non-GAAP$2.15B–(1) %
Nine Months 2026 Adjusted diluted EPSnon-GAAP$ 5.14––
Nine Months 2026 U.S. gross marginother82.5 %––
Nine Months 2026 International gross marginother70.3 %––

Segments

SegmentRevenueq/qy/y
Q3 2026 U.S.Companion animal revenue decreased 8%, reflecting macro-driven price sensitivity and competitive pressure in dermatology, as well as generic competition. Livestock revenue increased 5%, supported by strength across cattle, swine and poultry.$1.25B–(6) %
Q3 2026 InternationalCompanion animal revenue increased 1% on a reported basis and remained flat on an organic operational basis, while livestock revenue increased 8% on a reported basis and 9% on an organic operational basis, driven by growth in cattle and fish.$1.12B–4 %
Q3 2026 Companion AnimalDogs and Cats revenue was $ 1,492 and declined (6) %; Horses revenue was $ 73 and increased 6 %.$1.56B–(5) %
Q3 2026 LivestockCattle revenue was $ 439 and increased 6 %; Swine revenue was $ 120 and increased 3 %; Poultry revenue was $ 108 and increased 2 %; Fish revenue was $ 98 and increased 23 %; Sheep and other revenue was $ 32 and increased 10 %.$797M–7 %
Q3 2026 Contract Manufacturing & Human HealthOperational growth was 15 %.$ 29–12 %
Nine Months 2026 U.S.U.S. companion animal revenue declined (10) % and U.S. livestock revenue increased 11 %.$3.60B–(7) %
Nine Months 2026 InternationalInternational companion animal revenue increased 8 % and International livestock revenue increased 11 %.$3.44B–9 %
Nine Months 2026 Companion AnimalDogs and Cats revenue was $ 4,569 and declined (4) %; Horses revenue was $ 223 and increased 9 %.$4.79B–(4) %
Nine Months 2026 LivestockCattle revenue increased 13 %, Swine revenue increased 6 %, Poultry revenue increased 8 %, Fish revenue increased 14 %, and Sheep and other revenue increased 7 %.$2.25B–11 %
Nine Months 2026 Contract Manufacturing & Human HealthOperational growth was (9) %.$ 81–(9) %

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

Full Year 2026 as of November 5, 2026 outlook

  • Revenue$9,220 to $9,320
  • Operating expensesAdjusted SG&A expenses (b) $2,340 to $2,370; Adjusted R&D expenses (b) $705 to $715
  • Tax rateApproximately 20%
  • NoteOrganic operational results (a) (2)% to (1)%
  • NoteAdjusted cost of sales as a percentage of revenue (b) Approximately 29.0%
  • NoteAdjusted interest expense and other (income)/deductions-net (b) Approximately $215
  • NoteAdjusted diluted EPS (b) $6.25 to $6.35
  • NoteAdjusted net income (b) $2,600 to $2,640
  • NoteOrganic operational results (a)(c) (7)% to (5)%
  • NoteCertain significant items and acquisition and divestiture-related costs (d) Approximately $210
  • NoteReported diluted EPS $5.50 to $5.60
  • NoteNet income attributable to Zoetis $2,300 to $2,340

What drove it

  • International revenue increased 4 % in the third quarter, including 8 % reported growth in livestock revenue.
  • Livestock revenue increased 7 % overall, with fish revenue increasing 23 %.
  • International companion animal performance was led by parasiticides and osteoarthritis pain, partly offset by lower sales of key dermatology products.
  • Zoetis received FDA approval for Convenia RTU for Dogs in October and expects the product to be available to veterinarians in the first quarter of 2027.
  • Select approvals anticipated in 2027 are now expected in Q4 2026.

Concerns

  • U.S. revenue decreased (6) % and U.S. companion animal revenue decreased (8) %.
  • The company cited macro-driven price sensitivity, competitive pressure in dermatology and generic competition in U.S. companion animal.
  • GAAP net income attributable to Zoetis Inc. decreased (18) % and GAAP diluted EPS decreased (12) %.
  • Certain significant items were $ 133 pre-tax and included $ 89 of certain asset impairment charges.
  • Full-year revenue guidance was narrowed to $9,220 to $9,320, with organic operational growth of (2)% to (1)%.

What to watch

  • Whether U.S. companion animal demand, dermatology competition and generic competition continue to pressure revenue.
  • The pace of livestock growth, particularly cattle and fish, and the durability of International growth.
  • Delivery of full-year revenue guidance of $9,220 to $9,320 and adjusted diluted EPS guidance of $6.25 to $6.35.
  • Execution of the comprehensive cost and productivity program and the multi-year business process transformation program.
  • Timing of anticipated Q4 2026 product approvals and the first-quarter 2027 availability of Convenia RTU for Dogs.

Analysis

Zoetis reported third-quarter revenue of $ 2,391 million, down (1) % from $ 2,422 million. The revenue outcome reflected a (6) % decline in the U.S., which was only partly offset by 4 % growth in International. Companion Animal revenue declined (5) % to $ 1,565 million, while Livestock revenue increased 7 % to $ 797 million. Management attributed U.S. companion animal weakness to macro-driven price sensitivity, dermatology competition and generic competition.

International was the principal offset to U.S. weakness. International revenue was $ 1,116 million, with companion animal revenue increasing 1 % on a reported basis but flat on an organic operational basis. International livestock revenue increased 8 % reported and 9 % organic operational, driven by cattle and fish. Across the company, fish revenue increased 23 %, while cattle revenue increased 6 %.

Profitability declined on a GAAP basis. Net income attributable to Zoetis Inc. was $ 591 million, down (18) %, and diluted EPS was $ 1.44, down (12) %. The release reported $ 133 of pre-tax certain significant items, including $ 89 of certain asset impairment charges, as well as restructuring and cost-reduction/productivity initiatives. On a non-GAAP basis, adjusted net income was $ 720 million, down (5) %, while adjusted diluted EPS increased 3 % to $ 1.75. U.S. gross margin declined to 82.2 % from 83.2 %, whereas International gross margin increased to 68.9 % from 68.2 %.

For the first nine months, revenue was $ 7,121 million versus $ 7,094 million, while net income attributable to Zoetis Inc. declined to $ 1,883 million from $ 2,049 million. The company narrowed full-year revenue guidance to $9,220 to $9,320 and now expects organic operational revenue growth of (2)% to (1)%. It raised adjusted net income guidance to $2,600 to $2,640 and adjusted diluted EPS guidance to $6.25 to $6.35. The guide reflects foreign exchange rates as of October 20, 2026.

Portfolio development remains active, with FDA approval of Convenia RTU for Dogs in October and expected availability in the first quarter of 2027. Zoetis also stated that select approvals anticipated in 2027 are now expected in Q4 2026. The central operating issue remains whether livestock, diagnostics and international growth can continue to offset pressure in U.S. companion animal, while the company manages cost-reduction initiatives, impairment charges and business process transformation spending.

Management, verbatim

Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio.

Kristin Peck, Chief Executive Officer of Zoetis

We remain focused on defending our position and directing our resources where they can have the greatest impact. And with the scale, expertise, and pipeline to keep setting the pace of innovation in animal health, we are confident in our ability to create long-term value for customers and shareholders.

Kristin Peck, Chief Executive Officer of Zoetis

Not in the filing

stated, not guessed
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Cash and cash equivalents were not reported.
  • Debt was not reported.
  • Share repurchases were not reported.
  • Dividends were not reported.
  • Quarterly gross margin for total consolidated Zoetis was not reported as a standalone line item.
  • Prior-quarter comparisons were not reported.
  • A separately provided previous-release outlook for comparison with actual results was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of 2026

AlphAI · Earnings readZTS · second quarter of 2026

Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis

→Mixed quarter

Second-quarter revenue was flat and declined 1% on an organic operational basis, as a 7% decline in the U.S. segment offset 8% reported growth internationally. Adjusted net income and adjusted diluted EPS remained positive but declined 1% and rose 5%, respectively, on a reported basis, while full-year revenue and adjusted net income guidance call for organic operational declines.

Revenue
$2.5B
flat y/y
United States (U.S.)
$1.3B
decreasing 7% on both a reported and an organic operational basis y/y
EPS · non-GAAP
$1.87
increasing 5% y/y
Full Year 2026 outlook
$9.120 billion to $9.320 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenueGAAP$2.5B–flat
Revenue organic operational changenon-GAAPdecreasing 1%–decreasing 1%
Net incomeGAAP$691M–decreasing 5%
Diluted EPSGAAP$1.65 per diluted share–increasing 1%
Adjusted net incomenon-GAAP$781M–decreasing 1%
Adjusted net income organic operational changenon-GAAPdecreasing 2%–decreasing 2%
Adjusted diluted EPSnon-GAAP$1.87 per diluted share–increasing 5%
Adjusted diluted EPS organic operational changenon-GAAPincreasing 4%–increasing 4%
Adjusted net income exclusionsnon-GAAP$90M––

Segments

SegmentRevenueq/qy/y
United States (U.S.)Companion animal product sales decreased 11% due to continued softer end-market demand, price sensitivity, heightened competition, generic competition on Cerenia and Convenia, and lower Librela sales. Livestock product sales increased 23%, supported by cattle and poultry.$1.3B–decreasing 7% on both a reported and an organic operational basis
InternationalCompanion animal growth was led by parasiticides including Simparica Trio, Revolution and Stronghold, diagnostics, and OA pain launches. Livestock growth was driven by cattle and poultry.$1.2B–increasing 8% on a reported basis and 6% on an organic operational basis

Full Year 2026 outlook

  • Revenue$9.120 billion to $9.320 billion
  • NoteOrganic operational revenue growth of (3)% to (1)%
  • NoteReported net income of $2.330 billion to $2.380 billion
  • NoteAdjusted net income of $2.570 billion to $2.620 billion
  • NoteAdjusted net income organic operational growth of (9)% to (5)%
  • NoteReported diluted EPS of $5.55 to $5.65
  • NoteAdjusted diluted EPS of $6.15 to $6.25
  • NoteThis guidance reflects foreign exchange rates as of July 21, 2026.

What drove it

  • U.S. livestock product sales increased 23% on both a reported and organic operational basis, supported by strength across cattle and poultry.
  • International companion animal sales grew 8% on a reported basis and 5% on an organic operational basis, led by parasiticides, diagnostics, and OA pain products.
  • In July, Zoetis completed the acquisition of VitalRADS, a veterinary teleradiology services platform.
  • Lenivia and Portela launched in Canada and the EU and were approved in Great Britain. Lenivia was also approved in Switzerland.
  • Poulvac Procerta HVT-ND received marketing authorization from the European Commission in July.

Concerns

  • U.S. companion animal product sales decreased 11% due to continued softer end-market demand.
  • The dermatology franchise and Simparica Trio faced macro-driven price sensitivity and heightened competitive pressure.
  • Generic competition affected Cerenia and Convenia, and Librela sales were lower.
  • International growth was partially offset by lower sales of key dermatology products and challenging market conditions impacting the broader portfolio.
  • Full-year guidance calls for organic operational revenue growth of (3)% to (1)% and adjusted net income organic operational growth of (9)% to (5)%.

What to watch

  • Execution of targeted investments, innovation, and business development initiatives in response to pressured companion animal market conditions.
  • Demand trends for U.S. companion animal products, including the dermatology franchise, Simparica Trio and Librela.
  • The durability of livestock growth in cattle and poultry across the U.S. and International segments.
  • Growth contribution from international parasiticides, diagnostics, Lenivia and Portela.
  • Integration of VitalRADS and the expansion of Zoetis' Global Diagnostics and Virtual Reference Lab capabilities.

Analysis

Zoetis reported second-quarter 2026 revenue of $2.5 billion, flat compared with the second quarter of 2025 and decreasing 1% on an organic operational basis. Reported net income was $691 million, decreasing 5%, while diluted EPS was $1.65 per diluted share, increasing 1%. Adjusted net income was $781 million, decreasing 1% on a reported basis and decreasing 2% on an organic operational basis. Adjusted diluted EPS was $1.87 per diluted share, increasing 5% on a reported basis and increasing 4% on an organic operational basis.

The geographic mix was sharply divergent. U.S. revenue totaled $1.3 billion and decreased 7% on both a reported and organic operational basis. U.S. companion animal product sales decreased 11%, reflecting softer end-market demand, lower clinic visits, pet owner price sensitivity, heightened competition, generic competition on Cerenia and Convenia, and lower Librela sales. This was partly countered by U.S. livestock product sales growth of 23%, supported by cattle and poultry.

International revenue totaled $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis. International companion animal product sales grew 8% on a reported basis and 5% on an organic operational basis, led by parasiticides, diagnostics, and OA pain products. International livestock product sales grew 8% on a reported basis and 6% on an organic operational basis, driven by cattle and poultry. The release also identifies lower dermatology sales and challenging broader market conditions as offsets to International growth.

Management is continuing to invest in product approvals, launches and diagnostics capabilities. During the quarter and subsequent July activity described in the release, Zoetis advanced Poulvac Procerta HVT-ND, expanded Lenivia and Portela access, and completed the acquisition of VitalRADS. The company said its pipeline includes more than 12 potential blockbuster candidates. These initiatives are positioned as efforts to expand companion animal therapeutics and diagnostics while responding to disease threats affecting livestock.

The updated full-year 2026 outlook reflects the current operating environment. Zoetis guided to revenue of $9.120 billion to $9.320 billion, with organic operational revenue growth of (3)% to (1)%, and adjusted net income organic operational growth of (9)% to (5)%. The company also guided to reported net income of $2.330 billion to $2.380 billion, adjusted net income of $2.570 billion to $2.620 billion, reported diluted EPS of $5.55 to $5.65, and adjusted diluted EPS of $6.15 to $6.25. The guidance reflects foreign exchange rates as of July 21, 2026.

Management, verbatim

Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories.

Kristin Peck, Chief Executive Officer

At the same time, these dynamics reinforce the enduring attractiveness of the markets Zoetis has helped define and advance.

Kristin Peck, Chief Executive Officer

We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health.

Kristin Peck, Chief Executive Officer

Not in the filing

stated, not guessed
  • Period-end date
  • Prior-year revenue amount
  • Prior-quarter revenue amount and comparison
  • Prior-year and prior-quarter net income amounts
  • Prior-year and prior-quarter diluted EPS amounts
  • Prior-year and prior-quarter adjusted net income amounts
  • Prior-year and prior-quarter adjusted diluted EPS amounts
  • Gross profit and gross margin
  • Operating income and operating margin
  • Operating expenses
  • Operating cash flow
  • Free cash flow
  • Cash and cash equivalents
  • Debt
  • Share repurchases
  • Dividends
  • Prior full-year guidance for comparison
  • Segment prior-year revenue amounts
  • Segment prior-quarter revenue amounts
  • Exact prior-year amounts for U.S. companion animal and livestock product sales
  • Exact prior-year amounts for International companion animal and livestock product sales

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ZTS earnings dates

When is Zoetis's next earnings date?
AlphAI has no date for ZTS yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.